Odyssey Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ODTX in the last 30 days.
See all $ODTX insider activity →Odyssey Therapeutics reported Phase IIa trial data for OD-001, showing better efficacy at 20 mg dose. The company plans Phase IIb and combination studies for 2027 readouts. No serious adverse events were reported. Odyssey has $433M in cash, funding operations into 2H 2028. The company also plans to file a CTA for OD-002 this year.
Odyssey Therapeutics reported positive Phase 2a results for OD-001, meeting its primary endpoint with a 2.4-point mean modified Mayo score reduction. The 20 mg BID dose showed 27% clinical remission and 61% clinical response. Biomarkers indicated reduced inflammation, and the treatment was well-tolerated. The company plans to advance to Phase 2b with this dose.
Wall Street analysts issued updates on multiple companies. Biogen (BIIB) was upgraded to Overweight with a $300 target, First Solar (FSLR) to Buy with a $270 target, and Salesforce (CRM) to Buy with a $285 target. Adobe (ADBE) was downgraded to Underweight with a $225 target, and Snowflake (SNOW) to Accumulate with a $515 target. Robinhood (HOOD) was initiated with an Outperform rating and $130 target.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ODTX (Odyssey Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ODTX coverage spans financial news, earnings and ipo.
Positive Phase IIa data may lift the stock as investors anticipate further development and potential market approval.
Positive trial data is likely to lift the stock as investors anticipate further development and potential market approval.
Buy initiation may boost price.
The announcement adds a concrete development milestone, likely prompting short‑term buying interest.
Street initiation frames OD-001 as a potential commercial add-on therapy, supporting bullish sentiment into upcoming 2a combination readout.
AlphAI scores every news story that mentions ODTX with an AI model for sentiment and relevance, and aggregates insider trades from Odyssey Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Odyssey Therapeutics reported Phase IIa trial data for OD-001, showing better efficacy at 20 mg dose. The company plans Phase IIb and combination studies for 2027 readouts. No serious adverse events were reported. Odyssey has $433M in cash, funding operations into 2H 2028. The company also plans to file a CTA for OD-002 this year.
2 min readOdyssey Therapeutics reported positive Phase 2a results for OD-001, meeting its primary endpoint with a 2.4-point mean modified Mayo score reduction. The 20 mg BID dose showed 27% clinical remission and 61% clinical response. Biomarkers indicated reduced inflammation, and the treatment was well-tolerated. The company plans to advance to Phase 2b with this dose.
1 min readWall Street analysts issued updates on multiple companies. Biogen (BIIB) was upgraded to Overweight with a $300 target, First Solar (FSLR) to Buy with a $270 target, and Salesforce (CRM) to Buy with a $285 target. Adobe (ADBE) was downgraded to Underweight with a $225 target, and Snowflake (SNOW) to Accumulate with a $515 target. Robinhood (HOOD) was initiated with an Outperform rating and $130 target.
2 min readOdyssey Therapeutics (NASDAQ:ODTX) will present a Phase 2a trial design for OD-001 combined with vedolizumab in ulcerative colitis at the American College of Gastroenterology 2026 Annual Scientific Meeting. The trial will enroll up to 146 patients globally, with topline results expected in the second half of 2027. The company aims to target both innate and adaptive immunity in the disease.
2 min readUBS initiated coverage on Odyssey Therapeutics (ODTX) with a buy rating and $27 price target, citing potential in its IBD drug OD-001. The stock trades at $19, with consensus targets up to $44. UBS highlights positive Phase 2a trial results and a strong balance sheet. Additional analysts also rate ODTX positively, with targets up to $44.
3 min readRaymond James initiated coverage on Odyssey Therapeutics (ODTX) with an Outperform rating and a $42.00 price target. The stock is currently at $18.12, down 11% in the past week but up 10% year-to-date. The company is developing treatments for autoimmune and inflammatory conditions, with its lead asset OD-001 in Phase 2 trials. Analysts highlight the company's long-term potential and preclinical pipeline, though cash burn is noted.
2 min readOdyssey Therapeutics (ODTX) will present additional Phase 2a trial data for OD-001 in ulcerative colitis at UEG Week 2026. The presentation, by Bruce Sands, is scheduled for October 20. Odyssey will host a conference call the same day to discuss further data.
2 min readOdyssey Therapeutics (ODTX) reported Q2 2026 results with $433.1M cash, enough for operations into 2028. The company is advancing its lead drug OD-001, with Phase 2a data expected in October and two new trials planned. Net loss widened to $52.8M due to increased R&D spending. The company has no product revenue yet.
2 min readPro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
2 min readOdyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.
2 min read
